Our mission is to better differentiate Parkinson’s disease from related neurodegenerative disorders, enabling earlier diagnosis, more timely interventions, and better outcomes.

AMP Parkinson’s Disease and Related Disorders (AMP PDRD) builds on the infrastructure established during AMP Parkinson’s Disease (AMP PD), expanding on datasets to include a broader range of patients with Parkinson’s disease and other related disorders that share similar symptoms and biological characteristics, such as multiple system atrophy (MSA), Lewy body dementia (LBD), and progressive supranuclear palsy (PSP).

AMP PD integrated and harmonized data from diverse natural history and clinical trial studies, and streamlined data access to advance the discovery and development of therapeutics for people living with Parkinson’s disease.

AMP PDRD seeks to employ a data-driven approach to identify and validate biomarkers distinguishing Parkinson’s disease from related diseases, with an overarching goal to enhance the success of clinical trials and ultimately broaden treatment options for individuals affected by these conditions.

 

Goals
  • AMP PDRD seeks to build on progress to date by:

     

     

  • 1) Discovery and validation of PD and related synucleinopathy biomarkers: validating biomarkers such as alpha-synuclein seed amplification assays and other novel biomarkers to enhance patient stratification and therapeutic development while deepening understanding of PD’s and related synucleinopathies underlying mechanisms.

  • 2) Longitudinal multi-omic profiling: integrating existing while also generating new multi-omics data to identify molecular signatures in brain tissues and biofluids of patients with α-synucleinopathies and atypical Parkinsonisms, aiming to advance our understanding of pathophysiological mechanisms and disease heterogeneity.

  • 3) Multi-scale analysis framework: leveraging bioinformatic approaches for predictive modeling and developing analytical tools to identify and validate disease subtypes and endotypes to enable for precision medicine advancements.

No Approved Therapies

Parkinson’s Disease (PD) is a chronic and progressive neurological disease characterized by resting tremor, muscle rigidity, slowness of movement, impaired balance, and a shuffling gait. People with PD can also develop non-motor symptoms, such as behavioral changes and cognitive impairment. In the United States alone, it is estimated that more than 1 million people live with PD and approximately 90,000 Americans are diagnosed with the disease each year.

Early diagnosis is crucial for initiating appropriate treatment, and doctors have traditionally relied on a patient’s medical history, neurological examinations, and imaging tests to rule out other conditions with similar symptoms. A promising new diagnostic test can detect abnormal amounts of a protein called alpha-synuclein, a known biological characteristic of Parkinson’s disease, through a spinal tap or skin biopsy.

Once diagnosed, currently available treatments can manage symptoms, but no drugs have been approved to cure Parkinson’s or alter the course of the disease.

Identifying & Validating New Biomarkers

AMP PDRD represents a concerted effort to deepen our understanding of the underlying mechanisms of Parkinson’s disease, identify biomarkers for early detection, and develop more precise and effective treatments. One key aspect of the project is to validate biomarkers, including the presence of alpha-synuclein, as well as complementary biomarkers reflective of global corticolimbic mixed pathophysiology, such as Aβ1-42, tau, and phosphorylated tau (p-tau) or other novel biomarkers, that can differentiate Parkinson’s from related diseases, such as MSA, LBD and PSP. Along with identifying biomarkers for Parkinson’s, AMP PDRD will prioritize developing or validating platforms and tools for detecting these biomarkers through noninvasive methods such as blood or saliva.

In addition, researchers will gather and compare data from individuals at various stages of Parkinson’s to determine biomarkers that can indicate disease onset and progression, which could lead to more targeted and personalized treatment approaches. By validating biomarkers for early detection and disease progression, AMP PDRD will also facilitate recruiting the right participants for new drug trials and increase the success rate of those trials.

Partners

PUBLIC SECTOR PARTNERS

National Institute of Neurological Disorders and Stroke
National Institute on Aging
U.S. Food and Drug Administration

PRIVATE SECTOR PARTNERS
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner
NP-partner

Data sharing at this scale will accelerate the field’s progress by improving drug trials and fueling the clinical pipeline. MJFF looks forward to the results of bringing so many knowledgebases together through this public-private consortium.” 

-Todd Sherer, PhD, Chief Mission Officer of MJFF
nord logo

This vital collaboration with leading industry and non-profit partners supports our mission to deliver transformational innovations to those living with or at risk for synucleinopathies and their loved ones.

-Dr. Pablo Sardi, Global Head of Rare and Neurologic Diseases Research Therapeutic Area, Sanofi
nord logo
Contact

Donate

Donate to the FNIH today to support medical research that saves lives

Partner With Us

Work with the FNIH to accelerate medical breakthroughs for patients